Author

Sarah Cogoluegnes

Centre National de la Recherche Scientifique

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Andreas TrumppiD· 1 shared Elisa DonatoiD· 1 shared Frédéric LutoniD· 1 shared Isabelle Mus‐VeteauiD· 1 shared Michel FrancoiD· 1 shared Roberto WürthiD· 1 shared Sandra KovachkaiD· 1 shared Stéphane AzoulayiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andreas TrumppORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancer

Sarah Cogoluegnes, Sandra Kovachka, Thierry Dubois, Roberto Würth, Elisa Donato, Andreas Trumpp, Michel Franco, Frédéric Luton, Stéphane Azoulay, Isabelle Mus‐Veteau

This study shows that inhibiting PTCH1 drug efflux improves chemotherapy effectiveness in triple-negative breast cancer cells by increasing drug retention and reducing cell migration.

Translational Oncology · Apr 18, 2026Peer-reviewedCancer Biology